DocWire News Editors

DocwireNews

A recent study of KTE-X19 (also known as brexucabtagene autoleucel) supports the use of chimeric antigen receptor (CAR) T-cell therapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) whose disease did not respond to at least one line of chemoimmunotherapy and a Bruton tyrosine kinase (BTK) inhibitor. Charles Herbaux, MD, of Montpellier University Hospital in France, presented data from the first analysis of &ldquo;real-life&rdquo; application of KTE-X19 at the 2021 American Society of Hematology Annual Meeting.All patients with relapsed or refractory MCL who were registered in DESCAR-T, the French national registry for all patients with hematologic malignancies treated with CAR T cells, were eligible for the study. Investigators began collecting data at the time of the medical decision to treat with KTE-X19.Beginning on January 7, 2020, a total of 57 patients were enrolled in the study. In two cases, patients decided not to move forward with treatment, so KTE-X19 was not ordered. Eight patients were ultimately not infused with CAR T cells because of disease progression (n = 3), manufacturing failure (n = 3), cardiovascular disease (n = 1), and uncontrolled infection (n = 1).Among the 47 patients who were infused with KTE-X19, the median age at the time of registration with DESCAR-T was 67 years (range = 45-79). The majority of patients (93.6%) were male. Patients had received a median of three prior lines of treatment (range = 2-8), with 34% having previously undergone autologous stem cell transplant. At the time of enrollment, Ki67 was high (&gt;30%) in 78.6% of patients, Lactate dehydrogenase levels were elevated in 52.4% of patients, and 21.1% of patients had a performance status of &ge;2.The median time from CAR T-cell order and administration was 56 days (range = 35-134), during which 87.2% of patients underwent bridging therapy. After CAR T-cell infusion, median follow-up was 3.3 months (range = 0-12.6). Investigators used Lugano criteria to assess responses. Best overall response rate for the 42 patients who had at least one efficacy evaluation was 88%. This included complete responses (CR) for 61.9% of patients. At six months following KTE-X19 infusion, the progression-free survival rate was 57.9%, and median duration was 5.3 months.Cytokine release syndrome (CRS) was reported in 78.7% of patients, with neurotoxicity observed in 48.9%. Four patients (8.5%) experienced grade 3 or higher CRS or neurotoxicity. Intensive care unit transfer was required for 27.7% of patients, who were hospitalized for a median of five days. Among the 47 patients who were infused with KTE-X19, five deaths occurred. Four patients died of progressive disease and one of grade 5 CRS. &ldquo;The safety profile and the overall response rate are in line with previously published data,&rdquo; the authors wrote.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Real-Life Analysis of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma

ASH Annual Meeting and Exposition 2021

A recent study of KTE-X19 (also known as brexucabtagene autoleucel) supports the use of chimeric antigen receptor (CAR) T-cell therapy for the treatment of patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe